Actigall Related Published Studies
Well-designed clinical trials related to Actigall (Ursodiol)
Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. [2008.07.09]
Well-designed clinical trials possibly related to Actigall (Ursodiol)
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. [2009.09]
Physical activity as a determinant of fecal bile acid levels. [2009.05]
Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. [2009.04]
Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: A multicenter, randomized, double-blind clinical trial. [2008.08.12]
Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: A multicenter randomized controlled trial. [2008.03]
Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. [2008.02]
Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. [2008.02]
Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial. [2008.02]
Effects of long term hydrophilic bile acid therapy on in vitro contraction of gallbladder muscle strips in patients with cholesterol gallstones. [2007.08.28]
Kasai portoenterostomy: 12-year experience with a novel adjuvant therapy regimen. [2007.08]
Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. [2007.06.27]
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. [2006.12]
Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. [2006.09.15]
Effects of choleretics on bile compositions drained from patients with pigment gallstone. [2006.06]
Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. [2006.06]
[Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)] [2006.03]
Randomized prospective comparative study of ursodeoxycholic acid and S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis of pregnancy. [2006]
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. [2005.12]
High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. [2005.11]
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. [2005.11]
Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. [2005.10]
Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. [2005.09]
Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. [2005.08]
Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy. [2005.08]
Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. [2005.06.01]
Karyometry in rectal mucosa of patients with previous colorectal adenomas. [2005.06]
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. [2005.04]
Bioequivalence of a new liquid formulation of ursodeoxycholic acid (Ursofalk suspension) and Ursofalk capsules measured by plasma pharmacokinetics and biliary enrichment. [2005.03.15]
Failure of cholecystokinin-octapeptide to prevent TPN-associated gallstone disease. [2005.01]
Other research related to Actigall (Ursodiol)
Ursodiol in patients with parenteral nutrition-associated cholestasis. [2007.11]
Ursodiol in Patients with Parenteral Nutrition-Associated Cholestasis (November). [2007.10.02]
Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. [2005.01]
Other possibly related research studies
Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic Stem Cell Transplantation. [2007.02]
Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. [2007.01.11]
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. [2006.12]
[Effects of resolving phlegm method on fibrinolytic status in non-alcoholic steatohepatitis patients of phlegm and blood-stasis syndrome] [2006.12]
Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. [2006.12.21]
Gallstone disease: Primary and secondary prevention. [2006]
Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis. [2006.12]
Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. [2006.10]
[Granulomatous hepatitis successfully treated with ursodeoxycholic acid] [2006.08.06]
Ursodeoxycholic acid in the treatment of intraheptic cholestasis of pregnancy. [2006]
Identification of a novel 974C-->G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. [2006.10]
Primary sclerosing cholangitis: summary of a workshop. [2006.09]
Molecular mechanisms of cholestasis. [2006.07]
Recurrent primary biliary cirrhosis after liver transplantation--the disease and its management. [2006.05.03]
Routine gallbladder screening not necessary in patients undergoing laparoscopic Roux-en-Y gastric bypass. [2006.01]
Retrospective review of the preoperative biliary and gastrointestinal evaluation for gastric bypass surgery. [2006.01]
Incidence of symptomatic gallstones after gastric bypass: is prophylactic treatment really necessary? [2005.11]
Elective cholecystectomy after Roux-en-Y gastric bypass: why should asymptomatic gallstones be treated differently in morbidly obese patients? [2005.11]
Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. [2006.06]
Deflazacort for type-1 autoimmune hepatitis in a Korean girl. [2006.08]
Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. [2006.07]
Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. [2006.09]
Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. [2006.09.14]
Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. [2006.07.15]
Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. [2006.05]
Chemoprevention for colon cancer: new opportunities, fact or fiction? [2006.05]
Ursodeoxycholic acid treatment of vanishing bile duct syndromes. [2006.06.14]
Parenteral nutrition-associated liver disease in adult and pediatric patients. [2006.06]
Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis. [2006.06]
[Predisposing factors and results of pharmalogical treatment using ursodeoxycholic acid of gallbladder stones in children] [2006.02]
Role of ursodeoxycholic acid in lowering ALT in chronic liver disease. [2006.03]
Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans. [2006.05]
Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis. [2006.03]
Treatment of nonalcoholic fatty liver disease. [2006.04.14]
Effects of a 3-mo consumption of short-chain fructo-oligosaccharides on parameters of colorectal carcinogenesis in patients with or without small or large colorectal adenomas. [2005]
Primary biliary cirrhosis: when and why does the disease develop? [2006.04]
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. [2006.03]
Advances in prevention and treatment of hepatic disorders following hematopoietic cell transplantation. [2006]
Primary sclerosing cholangitis: diagnosis and management. [2006.02]
Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids. [2005.11]
The medical management of primary sclerosing cholangitis. [2006.02]
Autoimmune hemolytic anemia in an infant with giant cell hepatitis. [2006.03]
3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats. [2006.07.15]
Dexamethasone in the treatment of obstetric cholestasis: a case series. [2006.02]
24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. [2006.02]
Fetal death in a patient with intrahepatic cholestasis of pregnancy. [2006.02]
Rat liver fibrosis regresses better with pegylated interferon alpha2b and ursodeoxycholic acid treatments than spontaneous recovery. [2006.03]
Gallbladder bile composition in patients with Crohn 's disease. [2006.01.07]
Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts. [2006.02]
Management of hyperbilirubinemia and prevention of kernicterus in 20 patients with Crigler-Najjar disease. [2006.05]
Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. [2006.02]
Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. [2005.11]
[Possible treatment modalities of primary sclerosing cholangitis] [2005.12.04]
Review article: Drug therapy for non-alcoholic fatty liver disease. [2006.01.15]
Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. [2006.06.01]
Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. [2006.02]
Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. [2005.12]
Maternal cholestasis induces placental oxidative stress and apoptosis. Protective effect of ursodeoxycholic acid. [2006.01]
Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. [2006.04]
A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. [2005.12.12]
Medications associated with weight gain. [2005.12]
Demonstration of reversed flow in segmental branches of the portal vein with hand-held color Doppler ultrasonography after hematopoietic stem cell transplantation. [2005.12]
Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. [2005.09]
The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. [2005.11.01]
New therapeutical indications of ursodeoxycholic acid. [2005.09]
[The MDR3 gene mutation: a rare cause of progressive familial intrahepatic cholestasis (PFIC)] [2005.10]
Post-liver transplantation de novo hepatitis with overlap features. [2005.10]
Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. [2005.10]
|
